Coronavirus exposes the weak links in the pharma supply chain

17 March 2020
madhav_durbha_large

An overview of one of the issues that has been brought into focus by the coronavirus (COVID-19) outbreak by Madhav Durbha, group vice president, industry strategy, LLamasoft, in an Expert View piece.

While much is being written and said about the short-term supply chain challenges posed by the Coronavirus outbreak, this ongoing outbreak is also bringing to the fore some systemic challenges in the pharma supply chain.

Let us examine these here:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical